

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0283

Inventors: Salceda et al.

Serial No.: 10/001,870

Filing Date: November 20, 2001


Examiner: Kenneth R. Horlick

Group Art Unit: 1637

Title: Compositions and Methods Relating to
Prostate Specific Genes and Proteins

I, Kathleen A. Tyrrell, Registration No. 38,350,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: April 6, 2004


Kathleen A. Tyrrell Registration No. 38,350

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

() In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

04/19/2004 SLUANG1 00000007 501619 10001870

01 FC:1806 180.00 DA

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

(XX) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

(XX) Authorization to charge Deposit Account No. 50-1616 the fee of \$180.00 as set forth in §1.17(p) is provided.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.


Respectfully submitted


Kathleen A. Tyrrell
Registration No. 38,350

Date: April 6, 2004

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



2

Sheet 01 of 03

Form PTO-1449 Modified
U.S. Department of Commerce
Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

Docket No.
DEX-0283

Serial No.
10/001,870

Applicant
Salceda et al.

Filing Date
November 20, 2001

Group
1637

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	BA	WO 02/42329 A2	30-5-02	PCT	x	
	BB	WO 98/20129	14-5-98	PCT	x	

EXAMINER

DATE CONSIDERED



Form 101-1019 Modified		Docket No. DEX-0283	Serial No. 10/001,870
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Salceda et al.	
		Filing Date November 20, 2001	Group 1637
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	CA	SwisProt Accession No. Q99704 February 2003	
	CB	SwisProt Accession NO. P97465 February 2003	
	CC	NCBI Genbank Accession No. NM_001381 [gi:4503356] 19 March 1999 - 31 October 2000 with Revision History - the Revision History of 4755133 which replaces 4503356 is provided	
	CD	NCBI Genbank Accession No. NM_032603 [gi:14211942] 29 May 2001 - 29 June 2001 with Revision History - the Revision History of 22095373 which replaces 14211942 is provided	
	CE	NCBI Genbank Accession No. AK055944 [gi:16550796] 31 October 2001 with Revision History	
	CF	NCBI Genbank Accession No. U70987 [gi:1794260] 25 January 1997 - 6 March 1997 with Revision History	
	CG	NCBI Genbank Accession No. AF035299 [gi:2661055] 4 December 1997 - 1 September 2000 with Revision History	
	CH	NCBI Genbank Accession No. AF180527 [gi:6606314] 21 December 1999 - 7 July 2000 with Revision History	
	CI	Carpino et al., "p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells", Cell 1997 88:197-204	
EXAMINER		DATE CONSIDERED	



Sheet 03 of 03

Form PTO-1449 Modified		Docket No. DEX-0283	Serial No. 10/001,870
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Salceda et al.	
		Filing Date November 20, 2001	Group 1637
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	CJ	Hubert et al., "Molecular cloning of a truncated p62Dok1 isoform, p22Dok (del).", Eur. J. Immunogenet. 2000 27(3):145-148	
	CK	Liang et al., "Phosphatidylinositol 3-Kinase and Src Family Kinases Are Required for Phosphorylation and Membrane Recruitment of Dok-1 in c-Kit Signaling", J. Biol. Chem. 2002 277(16):13732-13788	
	CL	Nelms et al., "Dok1 encoding p62(dok) maps to mouse chromosome 6 and human chromosome 2 in a region of translocation in chronic lymphocytic leukemia", Genomics 1998 53(2):243-245	
	CM	Némorin et al., "Evidence That Lck-mediated Phosphorylation of p56 ^{dok} and p62 ^{dok} May Play a Role in CD2 Signaling", J. Biol. Chem. 2000 275(19):14590-14597	
	CN	Wisniewski et al., "A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blase populations", Leukemia 1994 8(4):688-693	
	CO	Yamakawa et al., "The rasGAP-binding protien, Dok-1, mediates activin signaling via serine/threonine kinase receptors", The EMBO Journal 2002 21(7):1684-1694	
EXAMINER		DATE CONSIDERED	